Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT

Bone Marrow Transplantation

Volumn 46, Issue 3, 2011, Pages 408-415

  Hebart, H ^a,b   Lengerke, C ^a   Ljungman, P ^c   Paya, C V ^d   Klingebiel, T ^a   Loeffler, J ^a,e   Pfaffenrath, S ^a   Lewensohn Fuchs, I ^c   Barkholt, L ^c   Tomiuk, J ^a   Meisner, C ^a   Lunenberg, J ^f   Top, B ^f   Razonable, R R ^d   Patel, R ^d   Litzow, M R ^d   Jahn, G ^a   Einsele, H ^a,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Center for Internal Medicine Schwäbisch Gmuend   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Mayo Clinic   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f BioMérieux Bv   (Netherlands)

Author keywords

allo SCT; antiviral therapy monitoring; CMV; NucliSens CMV pp67

Indexed keywords

FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; MESSENGER RNA;

ACCURACY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RNA, MESSENGER; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 79952538943     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.136     Document Type: Article

References (28)

1. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow Transplantation. N Engl J Med 1991; 325: 1601-1607.
2. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in re-cipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-1011.
3. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
4. Ehrnst A, Barkholt L, Lewensohn-Fuchs I, Ljungman P, Teodosiu O, Staland A et al. CMV PCR monitoring in leucocytes of transplant patients. Clin Diagn Virol 1995; 3: 139-153.
5. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraft-ment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071. (Pubitemid 26383133)
6. Zaia JA. Prevention of cytomegalovirus disease in hemato-poietic stem cell transplantation. Clin Infect Dis 2002; 35: 999-1004. (Pubitemid 35178318)
7. Boeckh M, Huang M, Ferrenberg J et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42: 1142-1148. (Pubitemid 38332838)
8. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytome-galovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-113. (Pubitemid 27327209)
9. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558. (Pubitemid 38351787)
10. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763. (Pubitemid 30189517)
11. Lengerke C, Ljubicic T, Meisner C, Loeffler J, Sinzger C, Einsele H et al. Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplant-ation. Bone Marrow Transplant 2006; 38: 53-60. (Pubitemid 43923090)
12. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036. (Pubitemid 30339241)
13. Boriskin YS, Fuller K, Powles RL, Vipond IB, Rice PS, Booth JC et al. Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site evaluation. J Clin Virol 2002; 24: 13-23. (Pubitemid 34016009)
14. Gerna G, Baldanti F, Middeldorp JM, Furione M, Zavattoni M, Lilleri D et al. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol 1999; 37: 902-911. (Pubitemid 29140587)
15. Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G et al. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 181-187. (Pubitemid 34993858)
16. Grundy JE, Ehrnst A, Einsele H, Emery VC, Hebart H, Prentice HG et al. A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood. J Clin Microbiol 1996; 34: 1166-1170. (Pubitemid 26126885)
17. Blok MJ, Goossens VJ, Vanherle SJ, Top B, Tacken N, Middeldorp JM et al. Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipients by nucleic acid sequence-based amplification. J Clin Microbiol 1998; 36: 1341-1346. (Pubitemid 28208024)
18. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495-503. (Pubitemid 20078123)
19. Kievits T, van Gemen B, van Strijp D, Schukkink R, Dircks M, Adriaanse H et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991; 35: 273-286.
20. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991; 77: 1104-1110.
21. Hebart H, Muller C, Loffler J, Jahn G, Einsele H. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17: 861-868. (Pubitemid 26156326)
22. Mendez JC, Procop GW, Espy MJ, Paya CV, Smith TF. Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi's sarcoma. J Clin Microbiol 1998; 36: 2220-2222. (Pubitemid 28324070)
23. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854-860. (Pubitemid 34274427)
24. Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186(Suppl 1): S99-S109.
25. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infec-tion after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164. (Pubitemid 34547067)
26. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalo-virus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178. (Pubitemid 23034801)
27. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781-1782. (Pubitemid 29102509)
28. Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoie-tic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003; 101: 5053-5060. (Pubitemid 36857773)